TOKYO (Reuters) -Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by ...

Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...

Airbus , Dassault Systemes and more than 90 smaller European technology companies and lobby groups have urged European ...

UBS released its annual report on Monday, with executive compensation being the most debated section. The remuneration for ...

The administration of President Donald Trump said on Thursday that the wind-down of a license allowing energy transactions ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

“Therefore, I decided to accept a new role as CEO of a US-based biotech. I want to thank [CEO Vas Narasimhan] for the opportunity to work at this great company and to everyone in oncology for ...

As it stands, Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US, although Novartis chief executive Vas Narasimhan said this morning he ...